Development of immunotherapy for cancer: Lessons from melanoma research

Yutaka Kawakami

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Identification of human melanoma antigens by various molecular biological and immunological techniques and evaluation of tumor reactive T cells in patients with the identified tumor antigen and HLA tetramer technology, not only provided us more profound understanding of anti-tumor immune responses in human, but also led to reveal basic problems in each step towards immunological tumor rejection, including systemic suppressive mechanisms such as regulatory T cell induction and local inhibitory environment in tumors. Based on these results obtained from the basic and clinical researches, various improvements have been applied for immunotherapy, including active immunization with modified antigenic peptides and recombinant virus, T cell adoptive transfer with lymphodepletive pretreatment, and administration of anti-CTLA-4 Ab, although further improvement is necessary. The translational research performed on melanoma, would facilitate development of immunotherapy for other cancers.

Original languageEnglish
Pages (from-to)87-98
Number of pages12
JournalJapanese Journal of Clinical Immunology
Issue number2
Publication statusPublished - 2004


  • Cancer
  • HLA tetramer
  • Immunotherapy
  • Melanoma
  • Tumor antigens

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Development of immunotherapy for cancer: Lessons from melanoma research'. Together they form a unique fingerprint.

Cite this